{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '9. The subject has the following baseline laboratory data:', 'absolute neutrophil count (ANC) > 1500/mm\u00b3', 'platelet count > 100 X 109/L', 'hemoglobin > 9 g/dL', 'serum total bilirubin V 1.5 X upper limit of normal (ULN)* or <3 X ULN for', \"subjects with Gilbert's disease\", 'creatinine clearance (CrCl) > 30 mL/min as estimated per institutional standards', 'or as measured by 24 hour urine collection (glomerular filtration rate [GFR]', 'can', 'also be used instead of CrCl)', 'ALT and AST 2.5 X ULN or 3 X ULN for subjects with liver metastases*', '*Docetaxel should not be chosen as a comparator for subjects if total bilirubin > ULN, or', 'if AST and/or ALT> 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN.', '10. Female subject must either:', 'Be of nonchildbearing potential:', 'Postmenopausal (defined as at least 1 year without any menses for which', 'there is no other obvious pathological or physiological cause) prior to', 'screening, or', 'Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy,', 'bilateral oophorectomy).', 'Note: Those who are amenorrheic due to an alternative medical cause are not', 'considered postmenopausal and must follow the criteria for childbearing', 'potential subjects.', 'Or, if of childbearing potential:', 'Agree not to try to become pregnant during the study and for at least', '6 months after the final study drug administration,', 'And have a negative urine or serum pregnancy test within 7 days prior to', 'Day 1 (Females with false positive results and documented verification of', 'negative pregnancy status are eligible for participation),', 'And if heterosexually active, agree to consistently use a condom plus 1 form', 'of highly effective birth control * per locally accepted standards starting at', 'screening and throughout the study period and for at least 6 months after the', 'final study drug administration.', '11. Female subject must agree not to breastfeed or donate ova starting at screening and', 'throughout the study period, and for at least 6 months after the final study drug', 'administration.', '14 Sep 2020', 'Astellas', 'Page 49 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12. A sexually active male subject with female partner(s) who is of childbearing potential is', 'eligible if:', 'Agrees to use a male condom starting at screening and continue throughout the', 'study treatment and for at least 6 months after final study drug administration If', 'the male subject has not had a vasectomy or is not sterile as defined below his', 'female partner(s) is utilizing 1 form of highly effective birth control* per locally', 'accepted standards starting at screening and continue throughout study treatment', 'and for at least 6 months after the male subject receives his final study drug', 'administration.', '*Highly effective forms of birth control include:', 'Consistent and correct usage of established hormonal contraceptives that inhibit', 'ovulation,', 'Established intrauterine device (IUD) or intrauterine hormone releasing system', '(IUS).', 'Bilateral tubal occlusion', 'Vasectomy (A vasectomy is a highly effective contraception method provided the', 'absence of sperm has been confirmed. If not, an additional highly effective method', 'of contraception should be used)', 'Male is sterile due to a bilateral orchiectomy or radical cystoprostatectomy/removal', 'of seminal vesicles', 'Sexual Abstinence is considered a highly effective method only if defined as', 'refraining from heterosexual activity during the entire period of risk associated with', 'the study drug. The reliability of sexual abstinence needs to be evaluated in relation', 'to the duration of the study and the preferred and usual lifestyle of the participant', 'Please note: Sexual abstinence is not sufficient as contraception method in Switzerland', '13. Male subject must not donate sperm starting at screening and throughout the study', 'period, and for at least 6 months after the final study drug administration.', '14. Male subject with a pregnant or breastfeeding partner(s) must agree to abstinence or use', 'a condom for the duration of the pregnancy or time partner is breastfeeding throughout', 'the study period and for at least 6 months after the final study drug administration.', '15. Subject agrees not to participate in another interventional study while on treatment in', 'present study.', 'Waivers to the inclusion criteria will NOT be allowed.', '14 Sep 2020', 'Astellas', 'Page 50 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}